TriangleDISEASE & TREATMENT SETTING
REZLIDHIA: refractory acute myeloid leukemia with IDH1 stated without a specific alteration, IDH1 mutation
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
REZLIDHIA is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
Broader topic: Acute Myeloid Leukemia
- Source population
- Not part of this definition
- Disease extent
- refractory
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- gene
- IDH1
- alteration
- stated without a specific alteration
- status
- present
- gene
- IDH1
- alteration
- mutation
- status
- present
- prior therapy
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for REZLIDHIA (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- REZLIDHIA is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
Study evidence for this setting
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice